Puma Biotechnology, Inc. PBYI
10.03 USD -0.66 (-6.17%)
Nov 5, 2026, 12:52 PM EST
10.03 Day range 10.88
4.58 52-week range 11.50
- YTD
- +68.57%
- 1 year
- +102.63%
News
businesswire.com Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) LOS ANGELES--(BUSINESS WIRE)--Puma biotechnology reported that it granted inducement awards in October 2026, as required under Nasdaq Listing Rule 5635(c)(4).
businesswire.com Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its third quarter 2026 results and host a conference call on Thursday, November 5, 2026, after the close.
zacks.com Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3? PBYI raised its 2026 Nerlynx sales outlook after 3.5% first-half 2026 growth, with Q3 revenues expected to reach $54-$56 million.
zacks.com 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
benzinga.com Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript On Thursday, Puma Biotechnology (NASDAQ:PBYI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…
businesswire.com Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of an inducement award to one new hire in Sept. 2026, as required under Nasdaq Listing Rule 5635(c)(4).
defenseworld.net Comparing TG Therapeutics (NASDAQ:TGTX) and Puma Biotechnology (NASDAQ:PBYI) Puma Biotechnology (NASDAQ: PBYI - Get Free Report) and TG Therapeutics (NASDAQ: TGTX - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two…
zacks.com PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
benzinga.com Puma Biotechnology Initiates ALISertib In CAncer Phase II Trial Of Alisertib In Combination With Paclitaxel For Treatment Of Patients With Advanced Small Cell Lung Cancer Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA®-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in…
businesswire.com Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.
businesswire.com Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference LOS ANGELES--(BUSINESS WIRE)--On Sept. 14, 2026, Puma Biotechnology CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conf.
seekingalpha.com Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise NERLYNX gives PBYI an established revenue stream that can support alisertib's development into a potential second oncology franchise. Currently, PBYI already has positive cash flows and a healthy…
businesswire.com Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).
defenseworld.net 3,804,736 Shares in Puma Biotechnology, Inc. $PBYI Bought by BlackRock Inc. BlackRock Inc. bought a new stake in Puma Biotechnology, Inc. (NASDAQ: PBYI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange…
zacks.com Is Puma Biotechnology (PBYI) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…
benzinga.com TD Cowen Maintains Hold on Puma Biotechnology, Raises Price Target to $6 TD Cowen analyst Marc Frahm maintains Puma Biotechnology (NASDAQ:PBYI) with a Hold and raises the price target from $5 to $6.
zacks.com PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.
seekingalpha.com Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
marketbeat.com Puma Biotechnology Q2 Earnings Call Highlights Puma Biotechnology NASDAQ: PBYI reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The…
zacks.com Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates Puma Biotech (PBYI) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.15 per share a year ago.
benzinga.com Puma Biotechnology Sees Q3 Sales $56.000M-$59.000M vs $60.500M Est Puma Biotechnology (NASDAQ:PBYI) sees Q3 sales of $56.000 million-$59.000 million vs $60.500 million analyst estimate.- benzinga.com Puma Biotechnology Raises FY2026 Sales Guidance from $222.000M-$229.000M to $224.000M-$231.000M vs $222.000M Est Puma Biotechnology (NASDAQ:PBYI) raises FY2026 sales outlook from $222.000 million-$229.000 million to $224.000 million-$231.000 million vs $222.000 million estimate.
benzinga.com Puma Biotechnology Q2 Adj. EPS $0.19 Beats $0.04 Estimate, Sales $53.600M Beat $53.000M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.04 by 375 percent. This is a 26.67 percent increase over earnings of…
businesswire.com Puma Biotechnology Reports Second Quarter 2026 Financial Results LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call beginning at 1:30 p.m. PT on Aug. 6, following release of its earnings results for 2Q-2026.
businesswire.com Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced its inducement awards granted for July 2026, as required under Nasdaq Listing Rule 5635(c)(4).
zacks.com Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's after-market session. The company's market cap stands at $2.0 million. Ironwood Pharmaceuticals…
benzinga.com Puma Biotechnology Sees Q2 Sales $52.000M-$55.000M vs $52.000M Est Second Quarter and Full Year 2026 Financial Outlook Second Quarter2026NewFull Year 2026PriorFull Year 2026Net Product Revenue$50–$52 million$202-206 million$194–$198 millionRoyalty Revenue$2–$3…- benzinga.com Puma Biotechnology Raises FY2026 Sales Guidance from $214.000M-$221.000M to $222.000M-$229.000M vs $218.000M Est Second Quarter and Full Year 2026 Financial Outlook Second Quarter2026NewFull Year 2026PriorFull Year 2026Net Product Revenue$50–$52 million$202-206 million$194–$198 millionRoyalty Revenue$2–$3…
benzinga.com Puma Biotechnology Q1 Adj. EPS $(0.04) Beats $(0.13) Estimate, Sales $44.800M Beat $42.000M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.13) by 69.23 percent. This is a 140 percent decrease over earnings of…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com UPDATE: Puma Biotechnology Sees FY2026 Sales $214.000M-$221.000M vs $220.000M Est Puma Biotechnology (NASDAQ:PBYI) sees FY2026 sales of $214.000 million-$221.000 million vs $220.000 million analyst estimate.
benzinga.com UPDATE: Puma Biotechnology Q4 Adj. EPS $0.29 Beats $0.23 Estimate, Sales $75.500M Beat $68.600M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.23 by 27.75 percent. This is a 32.56 percent decrease over earnings of…- benzinga.com Puma Biotechnology Sees Q1 Sales $38.000M-$42.000M vs $49.000M Est Puma Biotechnology (NASDAQ:PBYI) sees Q1 sales of $38.000 million-$42.000 million vs $49.000 million analyst estimate.
benzinga.com Puma Biotechnology Sees FY2026 Sales $214.000-$221.000M vs $220.000M Est Puma Biotechnology (NASDAQ:PBYI) sees FY2026 sales of $214.000-$221.000 million vs $220.000 million analyst estimate.
benzinga.com Puma Biotechnology Q4 Earnings Report: What Investors Need to Know 
benzinga.com Puma Biotechnology Q4 Adj. EPS $0.30 Beats $0.23 Estimate, Sales $75.500M Beat $68.600M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.23 by 32.16 percent. This is a 30.23 percent decrease over earnings of…
benzinga.com Earnings Scheduled For February 26, 2026 - benzinga.com Puma Biotechnology Added To Nasdaq Biotechnology Index, Effective Dec. 19 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective at the close of trading on Friday,…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Puma Biotechnology Raises FY2025 Sales Guidance from $212.000M-$222.000M to $220.000M-$223.000M vs $216.500M Est Puma Biotechnology (NASDAQ:PBYI) raises FY2025 sales outlook from $212.000 million-$222.000 million to $220.000 million-$223.000 million vs $216.500 million estimate.
- benzinga.com Puma Biotechnology Sees Q4 Sales $67.000M-$70.000M vs $66.600M Est Puma Biotechnology (NASDAQ:PBYI) sees Q4 sales of $67.000 million-$70.000 million vs $66.600 million analyst estimate.
- benzinga.com Puma Biotechnology Q3 Adj. EPS $0.21 Beats $0.04 Estimate, Sales $54.500M Beat $51.000M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.04 by 366.67 percent. This is a 53.33 percent decrease over earnings of…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Puma Biotechnology Affirms FY2025 Sales Guidance of $212.000M-$222.000M vs $217.800M Est Puma Biotechnology (NASDAQ:PBYI) affirms FY2025 sales outlook from $212.000 million-$222.000 million to $212.000 million-$222.000 million vs $217.800 million estimate.
- benzinga.com Puma Biotechnology Sees Q3 Sales $48.000M-$51.000M vs $60.000M Est Puma Biotechnology (NASDAQ:PBYI) sees Q3 sales of $48.000 million-$51.000 million vs $60.000 million analyst estimate.
- benzinga.com Puma Biotechnology Q2 Adj. EPS $0.15 Beats $0.10 Estimate, Sales $49.20M Miss $50.75M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.10 by 45.63 percent. This is a 400 percent increase over losses of…
- benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com Puma Biotechnology Q1 Adj. EPS $0.10 Beats $(0.02) Estimate, Sales $46.00M Beat $44.55M Estimate Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.02) by 600 percent. This is a 300 percent increase over losses of…
- benzinga.com Earnings Scheduled For May 8, 2025